Kristina M. Deligiannidis, MD
Feinstein Institutes for Medical Research, Northwell Health, Manhasset, New York, United States
Webinar
What's Next for PPD Treatment | Inhaled Mebufotenin (GH001) Phase 2a Results
July 29, 2026
Kristina Deligiannidis, MD, presents phase 2a results for inhaled GH001 (mebufotenin), a psychedelic-based therapeutic that produced same-day remission of postpartum depression in an open-label trial, with rapid clearance from...
Educational Activity
Evolving Research on Postpartum Depression Pathophysiology and Treatment
August 14, 2023
Research on neuroactive steroids reveals their role in perinatal depression, leading to development of novel therapeutics. These emerging treatments hold promise for faster onset and lasting effects.